Anti-IL17A (Cosentyx) (secukinumab biosimilar) mAb
Produktgrößen
50 µg
£478,00
12-9156-50UG
100 µg
£550,00
12-9156-100UG
Über dieses Produkt
- SKU:
- 12-9156
- Zusätzliche Namen:
- CTLA-8;CTLA8;IL-17;IL-17A;IL17
- Klonalität:
- Monoclonal
- Weitere Details:
- Secukinumab (Cosentyx) is a biologic medication used to treat psoriatic arthritis; moderate to severe plaque psoriasis. Biologics are medicines that are human-made through genetic engineering techniques and closely related to a protein that occurs naturally in the body. Secukinumab blocks an inflammatory protein called IL-17; thus improving joint pain and swelling from arthritis and rash from psoriasis. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
- Isotyp:
- IgG1
- Aufreinigung:
- Purified from cell culture supernatant by affinity chromatography
- Reaktivitäten:
- Human
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- Store at -20[o]C to -80[o]C for 12 months in lyophilized form. After reconstitution; if not intended for use within a month; aliquot and store at -80[o]C (Avoid repeated freezing and thawing).Lyophilized proteins are shipped at ambient temperature.
- Hersteller:
- Abeomics
- Typ:
- Antibodies:Monoclonal Antibody
- Datenblatt des Herstellers:12-9156 -FLOW.jpg
